This promising new application for Remplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company.

EDAP TMS reported Q2 2023 revenues of $15.52 million, a 0.9% YoY growth that missed estimates. In Q2 2023, HIFU’s total revenue growth stood at 63.6% (YoY). The procedure growth of Focal One shot up ...

The FDA has approved a novel diagnostic for prostate cancer that looks to improve upon the common screener for ...

Although the use of tissue-based gene expression testing for prostate cancer was found to be “highly variable in the United States at the regional level,” distinct regional trajectories of commercial ...

Cigna Expands Commercial and Medicare AdvantageCoverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test Expansion of coverage with Cigna now includes full menu of Company’s precision ...

Cleveland Clinic’s commercialization arm, Innovations, has spun off its fifth company this year in a joint project with an existing Cleveland startup. The new company is scooping up cancer diagnostic ...

Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer. This is an ...

Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed PERTH, Australia, Nov. 20, 2025 /PRNewswire/ -- Orthocell ...